in vitro News and Research

RSS

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).

7 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

Diagnosis of antiovarian autoantibodies in infertile women help in approaches for assisted reproduction

Studies on the ovarian antigens and its corresponding specific antibodies have showed the relationship between the incidences of antiovarian autoantibodies and the clinical mani-festation of ovarian dysfunction and infertility in women.

4 Jun 2010

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the fourth fiscal quarter and the full fiscal year ended March 31, 2010.

4 Jun 2010

YM BioSciences raises $3.2M through non-brokered private placement of common shares

YM BioSciences Inc., announced today that it has raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 common shares to be issued at US$1.27. The sale price is at no discount to the closing price of the shares on the NYSE Amex on June 1, 2010.

4 Jun 2010

TQ can suppress growth of aggressive PCa cell lines: Researchers

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.

2 Jun 2010

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

RepRegen™, the 'smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that three-month data from an in vivo study of its StronBone™ bioactive glass with Strontium demonstrated that it can generate bone quality in and around defects that appears by analytical tests to be significantly superior to a standard bone void filler in the control defect.

2 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

New research findings from fertility experts from Europe, the Americas, Asia & Australasia

31 May 2010

Researchers discover method to select sperm with highest DNA integrity

Researchers at Yale School of Medicine have discovered a method to select sperm with the highest DNA integrity in a bid to improve male fertility. The method is comparable to that of the egg's natural selection abilities, according to the study published in the June/July issue of the Journal of Andrology.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.

29 May 2010

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea.

28 May 2010

Low frequency ultrasound can heal and regenerate body tissues

When we think of ultrasound, it's usually imaging the inside of the body that springs to mind. However, while ultrasound imaging typically requires frequencies that are 50 to 2500 times higher than those human ear can detect, recent increasing evidence indicates that ultrasound at lower frequency can also be used to help certain body tissues to heal and regenerate. Now research that appears in Open Access Journal of Tissue Engineering published by SAGE-Hindawi suggests that ultrasound could also help tissue grafts to survive and thrive following surgery.

28 May 2010

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29th through June 1st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.

28 May 2010

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. The Elecsys Anti-HCV assay is an in-vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma.

From Roche Sequencing and Life Science 28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

CardioGenics Holdings announces further update on status of its agreement with Merck Chimie

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care™ Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced today a further update regarding the status of its agreement with Merck Chimie S.A.S., one of the largest manufacturers and distributors of magnetic beads for the diagnostics market.

28 May 2010

in vitro News and Research

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Diagnosis of antiovarian autoantibodies in infertile women help in approaches for assisted reproduction

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

YM BioSciences raises $3.2M through non-brokered private placement of common shares

TQ can suppress growth of aggressive PCa cell lines: Researchers

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

New technique transforms iPS cells into natural tumor killers

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

Researchers discover method to select sperm with highest DNA integrity

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Low frequency ultrasound can heal and regenerate body tissues

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

CardioGenics Holdings announces further update on status of its agreement with Merck Chimie

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News